Core Viewpoint - The stock of Innovent Biologics (01801) rose over 4%, reaching HKD 98, with a trading volume of HKD 405 million, following the acceptance of its weight management drug application by the NMPA [1] Group 1: Company Developments - Innovent Biologics announced that its application for the high-dose 9mg injection of the drug Senilemi (a dual receptor agonist for glucagon and GLP-1) for long-term weight control in adults with moderate to severe obesity has been accepted by the NMPA [1] - The application is based on the outstanding results from the Phase III clinical study GLORY-2 (NCT06164873) conducted in China, which achieved all primary and key secondary endpoints [1] - Senilemi 9mg is currently the only GLP-1 class drug that can achieve over 20% weight loss after one year of treatment through a two-step dose titration, providing effective weight management evidence for moderate to severe obesity patients in China [1]
信达生物涨超4% 玛仕度肽注射液高剂量9mg上市申请获受理